This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data
by Zacks Equity Research
Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.
UnitedHealthcare Ties Up to Improve Eye Health of Members
by Zacks Equity Research
UnitedHealth Group's (UNH) UnitedHealthcare business collaborates with GlassesUSA.com for providing improved eye care to its eligible members.
Sanofi's Blood Disorder Candidate Gets FDA's Priority Review
by Zacks Equity Research
The FDA grants priority review to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).
MEDNAX Affiliate Ties Up With CDI to Improve Patient Care
by Zacks Equity Research
MEDNAX's (MD) affiliate Jefferson Radiology collaborates with CDI for providing enhanced healthcare services to the Springfield community.
Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.
Is Alexion Pharmaceuticals (ALXN) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Alexion (ALXN) Beats on Q1 Earnings & Sales, Lowers Guidance
by Zacks Equity Research
Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.
Add Value to Your Portfolio With 5 High Earnings Yield Picks
by Rimmi Singhi
If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.
Alexion Pharmaceuticals (ALXN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 19.26% and 6.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2020 results.
Should You Buy Alexion (ALXN) Ahead of Earnings?
by Zacks Equity Research
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide pipeline updates along with financial numbers for the first quarter in its impending earnings release.
Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q1 results.
Factors Setting the Tone for Bristol-Myers (BMY) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2020 results.
Cronos (CRON) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q1 results.
Zacks.com featured highlights include: LAUR, IMKTA, ALXN and CSIQ
by Zacks Equity Research
Zacks.com featured highlights include: LAUR, IMKTA, ALXN and CSIQ
Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.
Add Value to Your Portfolio With These 4 Low P/CF Stocks
by Sumit Singh
In value investing, investors pick stocks that are cheap but fundamentally sound. So, the chance of outperformance is high when the market moves higher.
Alexion Pharmaceuticals (ALXN) Stock Moves -0.9%: What You Should Know
by Zacks Equity Research
In the latest trading session, Alexion Pharmaceuticals (ALXN) closed at $107.47, marking a -0.9% move from the previous day.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.